Summary of Key Information:
Reporting Period (Quarter/Year): Quarter and Half Year ended September 30, 2026
Nature of Filing / Announcement: Outcome of Board Meeting under Regulation 30 & 33 of SEBI (LODR) Regulations, 2015
Audit Opinion:
Clean (Unmodified Review Report)
Key Financial Highlights [Amount in ₹ Lakhs]:
Standalone Results:
Revenue from Operations: Q2 FY27: ₹12,606.54 (vs Q2 FY26: ₹9,942.42, +26.8% YoY); H1 FY27: ₹25,309.45 (vs H1 FY26: ₹17,743.12, +42.6% YoY)
Total Income: Q2 FY27: ₹12,996.04; H1 FY27: ₹26,093.21
Net Profit: Q2 FY27: ₹112.24 (vs Q2 FY26: ₹990.85, -88.7% YoY); H1 FY27: ₹301.96 (vs H1 FY26: ₹1,581.29, -80.9% YoY)
EPS: Q2 FY27: ₹0.32 (Basic & Diluted); H1 FY27: ₹0.87 (Basic & Diluted)
Other Equity: As of September 30, 2026: ₹85,772.35 (Unaudited)
Cash and Cash Equivalents: As of September 30, 2026: ₹0.92
Debt: Not Specified
Consolidated Results:
Revenue from Operations: Q2 FY27: ₹19,933.14 (vs Q2 FY26: ₹12,894.82, +54.6% YoY); H1 FY27: ₹37,293.37 (vs H1 FY26: ₹23,253.08, +60.4% YoY)
Total Income: Q2 FY27: ₹20,418.83; H1 FY27: ₹37,983.40
Net Profit: Q2 FY27: Loss of ₹2,596.02 (vs Q2 FY26: Loss of ₹1,619.38); H1 FY27: Loss of ₹6,990.49 (vs H1 FY26: Loss of ₹2,997.17)
EPS: Q2 FY27: -₹7.39 (Basic & Diluted); H1 FY27: -₹19.96 (Basic & Diluted)
Other Equity: As of September 30, 2026: ₹59,096.52 (Unaudited)
Cash and Cash Equivalents: As of September 30, 2026: ₹862.04
Debt: Not Specified
Segment-wise Performance:
The Company has concluded that it is engaged in a single operating segment as per Ind AS 108.
Corporate Actions:
Not Specified
Other Significant Information:
The company invested ₹11,952.23 lakhs by subscribing 2,35,512 equity shares of Davaindia Health Mart Limited (wholly owned subsidiary) on a preferential basis for conversion of outstanding unsecured loan with accumulated interest.
The issue price was ₹5,075 per equity share (including premium of ₹5,065).
The consolidated results include adoption of Ind AS 116 'Leases', recognizing Right-of-Use Asset of ₹22,252.91 lakhs and Lease Liability of ₹23,910.62 lakhs as at September 30, 2026.
Impact of lease adoption on consolidated profit: Q2 FY27: ₹193.41 lakhs; H1 FY27: ₹372.53 lakhs.
Entities included in consolidation:
1. Zota Health Care Limited (Parent)
2. Zota Healthcare Lanka (Pvt) Ltd (Wholly Owned Subsidiary)
3. Davaindia Health Mart Limited (Wholly Owned Subsidiary)
4. Zota Nex Tech Limited (Wholly Owned Subsidiary)
5. Everyday Herbal Beauty Care Limited (Subsidiary)
6. Everyday Herbal Beauty And Wellness Care Private Limited (Subsidiary)
7. Curexis Ventures Private Limited (Wholly Owned Subsidiary)
8. Globotask IT Consultancy Services Private Limited (Subsidiary)
9. KMHP Ventures Limited (Wholly Owned Subsidiary)
Exceptional items or one-time adjustments:
Not Specified
Change in accounting policy:
Not Specified
Forward-looking guidance or management outlook:
Not Specified